Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AQSTNASDAQ:ATXSNASDAQ:AURANASDAQ:INCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAQSTAquestive Therapeutics$2.92+2.8%$2.77$2.20▼$5.80$288.70M2.591.48 million shs1.00 million shsATXSAstria Therapeutics$5.16+0.8%$5.45$3.56▼$12.92$291.20M0.68372,747 shs361,269 shsAURAAura Biosciences$5.83+4.9%$6.36$4.84▼$12.38$279.25M0.43202,337 shs161,112 shsINCRInterCure$1.57+3.6%$1.46$1.17▼$3.72$71.73M1.2833,901 shs7,455 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAQSTAquestive Therapeutics+2.82%+3.55%+0.69%-5.19%-13.10%ATXSAstria Therapeutics+0.78%-0.58%-3.37%-31.11%-43.79%AURAAura Biosciences+4.86%+1.22%-0.51%-26.48%-21.22%INCRInterCure+3.55%+7.44%+12.43%-4.32%-46.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAQSTAquestive Therapeutics1.5236 of 5 stars3.62.00.00.02.20.00.0ATXSAstria Therapeutics2.7927 of 5 stars4.61.00.00.03.21.70.0AURAAura Biosciences2.1673 of 5 stars3.62.00.00.02.12.50.0INCRInterCure1.2698 of 5 stars0.05.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAQSTAquestive Therapeutics 3.14Buy$10.67265.30% UpsideATXSAstria Therapeutics 3.38Buy$30.00481.40% UpsideAURAAura Biosciences 3.25Buy$22.75290.22% UpsideINCRInterCure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest INCR, ATXS, AQST, and AURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$47.004/2/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/26/2025AURAAura BiosciencesJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$19.003/26/2025AURAAura BiosciencesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform3/25/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$25.003/24/2025AURAAura BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/12/2025ATXSAstria TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.00 ➝ $28.003/11/2025ATXSAstria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.003/10/2025AQSTAquestive TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.003/7/2025AQSTAquestive TherapeuticsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$7.00(Data available from 5/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAQSTAquestive Therapeutics$57.56M5.02N/AN/A($1.59) per share-1.84ATXSAstria TherapeuticsN/AN/AN/AN/A$3.33 per shareN/AAURAAura BiosciencesN/AN/AN/AN/A$4.58 per shareN/AINCRInterCure$272.67M0.26N/AN/A$2.72 per share0.58Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAQSTAquestive Therapeutics-$7.87M-$0.52N/AN/AN/A-59.75%N/A-33.96%5/6/2025 (Estimated)ATXSAstria Therapeutics-$72.89M-$1.67N/AN/AN/AN/A-43.58%-29.36%5/8/2025 (Estimated)AURAAura Biosciences-$76.41M-$1.75N/AN/AN/AN/A-41.57%-36.43%5/8/2025 (Estimated)INCRInterCure-$16.83MN/A0.00∞N/AN/AN/AN/A5/7/2025 (Estimated)Latest INCR, ATXS, AQST, and AURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025ATXSAstria Therapeutics-$0.48N/AN/AN/AN/AN/A5/8/2025Q1 2025AURAAura Biosciences-$0.45N/AN/AN/AN/AN/A5/6/2025Q1 2025AQSTAquestive Therapeutics-$0.17N/AN/AN/A$12.23 millionN/A3/24/2025Q4 2024AURAAura Biosciences-$0.43-$0.52-$0.09-$0.52N/AN/A3/11/2025Q4 2024ATXSAstria Therapeutics-$0.45-$0.44+$0.01-$0.44N/AN/A3/5/2025Q4 2024AQSTAquestive Therapeutics-$0.14-$0.19-$0.05-$0.19$13.11 million$11.87 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAQSTAquestive TherapeuticsN/AN/AN/AN/AN/AATXSAstria TherapeuticsN/AN/AN/AN/AN/AAURAAura BiosciencesN/AN/AN/AN/AN/AINCRInterCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAQSTAquestive TherapeuticsN/A6.375.91ATXSAstria TherapeuticsN/A22.3822.38AURAAura BiosciencesN/A12.4712.47INCRInterCure0.151.781.15Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAQSTAquestive Therapeutics32.45%ATXSAstria Therapeutics98.98%AURAAura Biosciences96.75%INCRInterCure8.34%Insider OwnershipCompanyInsider OwnershipAQSTAquestive Therapeutics7.85%ATXSAstria Therapeutics2.90%AURAAura Biosciences5.40%INCRInterCure0.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAQSTAquestive Therapeutics16098.87 million84.02 millionOptionableATXSAstria Therapeutics3056.43 million54.80 millionOptionableAURAAura Biosciences5050.23 million47.25 millionNot OptionableINCRInterCure35045.57 million45.46 millionOptionableINCR, ATXS, AQST, and AURA HeadlinesRecent News About These CompaniesInterCure Ltd. (NASDAQ:INCR) Short Interest UpdateApril 22, 2025 | marketbeat.comInterCure (NASDAQ:INCR) Shares Up 3.5% - Here's WhyApril 18, 2025 | marketbeat.comInterCure names Alexander Rabinovich as Chairman, replacing Ehud BarakFebruary 15, 2025 | markets.businessinsider.comInterCure Names Alexander Rabinovich as Chairman Replacing Ehud BarakFebruary 12, 2025 | prnewswire.comInterCure Secures Major Funding to Boost GrowthDecember 22, 2024 | markets.businessinsider.comCannabis co InterCure raising NIS 66m for Nir Oz facilityDecember 22, 2024 | en.globes.co.ilInterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz FacilityDecember 20, 2024 | prnewswire.comRising High: Exclusive talk with house of brands Carma HoldCoNovember 7, 2024 | markets.businessinsider.comInterCure Ltd. (INCR)October 16, 2024 | finance.yahoo.comAre Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed CompanySeptember 14, 2024 | benzinga.comInterCure partners with Cookies to launch cannabis pharmacies in GermanyAugust 30, 2024 | investing.comTop Seller Of Pharmaceutical Cannabis Outside US Grew By Double-Digits, Focuses On GermanyAugust 30, 2024 | msn.comInterCure Ltd.: InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 millionAugust 30, 2024 | finanznachrichten.deInterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 millionAugust 29, 2024 | globenewswire.comInterCure Announces Expansion of its Strategic partnership with Cookies to GermanyAugust 28, 2024 | finance.yahoo.comElectreon Wireless Ltd (ELWS)July 31, 2024 | investing.comAsset-Light Expansion Into $8B German Market Adds Potential To This Cannabis Stock On NASDAQMay 24, 2024 | markets.businessinsider.comInterCure to Participate in Canaccord Genuity’s 8th Annual Global Cannabis ConferenceMay 22, 2024 | finance.yahoo.comInterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis ConferenceMay 22, 2024 | businesswire.comInterCure Reports Strong FY2023: Performance Paves the Way for Global ExpansionMay 2, 2024 | msn.comInterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 millionMay 1, 2024 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Industry Behemoths Are Rewarding Investors With Dividend BumpsBy Leo Miller | April 28, 2025View 3 Industry Behemoths Are Rewarding Investors With Dividend BumpsAlphabet Rebounds After Strong Earnings and Buyback AnnouncementBy Ryan Hasson | April 28, 2025View Alphabet Rebounds After Strong Earnings and Buyback Announcement3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomBy Nathan Reiff | April 10, 2025View 3 Robotics Stocks That Could Benefit From U.S. Manufacturing BoomCoca-Cola Company Stock Can Bubble to New Highs This YearBy Thomas Hughes | April 29, 2025View Coca-Cola Company Stock Can Bubble to New Highs This YearChipotle Mexican Grill Serves Smoking Hot Entry Point in Q2By Thomas Hughes | April 27, 2025View Chipotle Mexican Grill Serves Smoking Hot Entry Point in Q2INCR, ATXS, AQST, and AURA Company DescriptionsAquestive Therapeutics NASDAQ:AQST$2.92 +0.08 (+2.82%) As of 04/30/2025 04:00 PM EasternAquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.Astria Therapeutics NASDAQ:ATXS$5.16 +0.04 (+0.78%) As of 04/30/2025 04:00 PM EasternAstria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Aura Biosciences NASDAQ:AURA$5.83 +0.27 (+4.86%) As of 04/30/2025 04:00 PM EasternAura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.InterCure NASDAQ:INCR$1.57 +0.05 (+3.55%) As of 04/30/2025 03:56 PM EasternInterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Hims & Hers Stock Soars on Novo Nordisk Collaboration 3 Dividend Kings Outshining the Market in 2025 Tesla's Band-Aid Has Been Ripped Off: Rally Mode Engaged Amazon's Earnings Will Make or Break the Stock's Comeback Why D-Wave's Project With Davidson Is a Game-Changer For Quantum NXP Semiconductors: A Buy-and-Hold Stock in the Buy Zone Joby Aviation Shares Eye Breakout After Transition Flight Win Altria’s Resilient Strategy Keeps It a Top Dividend Play in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
